Satellos Bioscience Inc.: Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million

Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Dennis Riedl ,Christina Cameron ,Ryan Mitchell ,Geoff Mackay ,Michael Rudnicki ,Frank Gleeson ,Amphotericinb Technologies Inc ,Communications At Satellos Bioscience Inc ,Regulatory Services Provider ,Newsfile Corp ,Company Board ,Company The Debentures ,Satellos Bioscience Inc ,Venture Exchange ,Business Development ,Each Unit ,Board Chair ,Multilateral Instrument ,Minority Security Holders ,Special Transactions ,Bonus Shares ,Closing Date ,Cash Fee ,Satellos Bioscience ,Satellos ,Ioscience ,Nnounces ,Roposed ,Rokered ,Offering ,Insecured ,Convertible ,Debentures ,Billion ,